| Title |
A new era of cancer treatment: carbon nanotubes as drug delivery tools
|
|---|---|
| Published in |
International Journal of Nanomedicine, November 2011
|
| DOI | 10.2147/ijn.s16923 |
| Pubmed ID | |
| Authors |
Seyed Yazdan Madani, Naghmeh Naderi, Oshani Dissanayake, Aaron Tan, Alexander M Seifalian |
| Abstract |
Cancer is a generic term that encompasses a group of diseases characterized by an uncontrolled proliferation of cells. There are over 200 different types of cancer, each of which gains its nomenclature according to the type of tissue the cell originates in. Many patients who succumb to cancer do not die as a result of the primary tumor, but because of the systemic effects of metastases on other regions away from the original site. One of the aims of cancer therapy is to prevent the metastatic process as early as possible. There are currently many therapies in clinical use, and recent advances in biotechnology lend credence to the potential of nanotechnology in the fight against cancer. Nanomaterials such as carbon nanotubes (CNTs), quantum dots, and dendrimers have unique properties that can be exploited for diagnostic purposes, thermal ablation, and drug delivery in cancer. CNTs are tubular materials with nanometer-sized diameters and axial symmetry, giving them unique properties that can be exploited in the diagnosis and treatment of cancer. In addition, CNTs have the potential to deliver drugs directly to targeted cells and tissues. Alongside the rapid advances in the development of nanotechnology-based materials, elucidating the toxicity of nanoparticles is also imperative. Hence, in this review, we seek to explore the biomedical applications of CNTs, with particular emphasis on their use as therapeutic platforms in oncology. |
Mendeley readers
The data shown below were compiled from readership statistics for 321 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Turkey | 1 | <1% |
| Netherlands | 1 | <1% |
| Pakistan | 1 | <1% |
| Brazil | 1 | <1% |
| India | 1 | <1% |
| United Kingdom | 1 | <1% |
| Egypt | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| Other | 3 | <1% |
| Unknown | 309 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 58 | 18% |
| Student > Ph. D. Student | 52 | 16% |
| Student > Bachelor | 43 | 13% |
| Researcher | 24 | 7% |
| Student > Doctoral Student | 13 | 4% |
| Other | 37 | 12% |
| Unknown | 94 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 52 | 16% |
| Agricultural and Biological Sciences | 28 | 9% |
| Biochemistry, Genetics and Molecular Biology | 28 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 7% |
| Engineering | 22 | 7% |
| Other | 62 | 19% |
| Unknown | 107 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2014.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from International Journal of Nanomedicine
#1,077
of 4,123 outputs
Outputs of similar age
#52,343
of 153,814 outputs
Outputs of similar age from International Journal of Nanomedicine
#21
of 59 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,123 research outputs from this source. They receive a mean Attention Score of 4.7. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 153,814 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.